Epstein‑Barr virus (EBV) is one of the most common viruses on Earth, yet it rarely makes headlines. Most people catch it at some point in their lives, often without knowing it. But beneath its quiet reputation, EBV is linked to a surprising number of serious health problems – from infectious mononucleosis (“mono”) to certain cancers and even autoimmune diseases.
A new study published in Cell Reports Medicine reveals a major step forward: scientists have created fully human antibodies in a special type of mouse that can block EBV from infecting cells. Even more importantly, these antibodies protected humanized mice from EBV infection, offering a potential path toward the first targeted therapy for this virus.
For a virus that infects more than 90% of adults worldwide, this is a big deal.
Why EBV Matters More Than Most People Realize
EBV is a member of the herpesvirus family, and like its relatives, it stays in the body for life once you’re infected. For many people, it causes no symptoms. But for others, EBV can lead to:
- Infectious mononucleosis (“mono”), especially in teens and young adults
- Certain cancers, including Hodgkin lymphoma, Burkitt lymphoma, and nasopharyngeal carcinoma
- Autoimmune diseases, such as multiple sclerosis and lupus
- Life‑threatening complications in transplant patients, including post‑transplant lymphoproliferative disease (PTLD)
Globally, EBV is linked to over 350,000 cancer cases and more than 200,000 deaths every year.
Despite this enormous impact, there is no EBV‑specific treatment or vaccine.
That’s why the new research is so significant: it shows that targeted antibodies – designed to block the virus from entering cells – could become a real tool for preventing EBV‑related disease.
Stop Overpaying for Meds.
Coupons aren’t your only option – see if safer, more effective, and lower-cost alternatives are available. It’s fast, personalized, and 100% free. Learn More →
How EBV Infects the Body
To understand why these new antibodies matter, it helps to know how EBV gets into cells.
EBV mainly infects two types of cells:
- B cells, which are part of the immune system
- Epithelial cells, which line surfaces like the throat and nose
To enter these cells, EBV uses two key “grappling hooks” on its surface:
- gp350 – helps the virus attach to B cells
- gp42 – helps the virus fuse with B cells and complete infection
If you block either of these proteins, you can stop the virus from getting inside.
The challenge? Most existing antibodies that target gp350 or gp42 are not fully human, meaning they can trigger immune reactions if used as a therapy.
The new study solves that problem.
The Breakthrough: Human Antibodies Made in Transgenic Mice
Researchers used a special type of mouse called ATX‑GK, engineered to produce human antibody genes instead of mouse ones. When these mice were immunized with EBV proteins, their immune systems created human‑like antibodies that could be used in people.
From these mice, the team isolated:
- Two antibodies targeting gp350
- Eight antibodies targeting gp42
These antibodies were then tested in a series of experiments to see how well they could block EBV infection.
What the Scientists Found
1. The antibodies strongly blocked EBV from infecting B cells
The gp350 antibodies prevented the virus from attaching to the B‑cell receptor CD21, which is the first step in infection. One antibody, called ATX‑350‑2, was especially potent – nearly as strong as the best existing anti‑EBV antibodies.
The gp42 antibodies were even more impressive. Because gp42 is essential for EBV to fuse with B cells, blocking it shuts down infection at a critical step.
2. The antibodies worked in multiple cell types
EBV infects both immune cells and epithelial cells. The new antibodies were tested in both, and several showed strong neutralizing activity.
3. The antibodies protected humanized mice from EBV infection
This is the most important finding.
When the researchers gave the gp42 antibody to mice engineered with human immune systems, then exposed them to EBV, the antibody:
- Prevented detectable virus in the blood
- Prevented spleen enlargement (a hallmark of EBV infection)
- Prevented viral DNA from appearing in the spleen
The gp350 antibody also helped, though not as completely.
This is the first time fully human antibodies from a transgenic mouse have shown such strong protection against EBV.
Why This Matters for Everyday People
EBV is far more than “the mono virus”
Most people think of EBV as a teenage rite of passage – something that causes fatigue and swollen glands for a few weeks. But research over the past decade has revealed a much more serious picture.
EBV is strongly linked to:
Multiple sclerosis
- A landmark 2022 study of 10 million U.S. military personnel found that EBV infection increases MS risk 32‑fold.
Autoimmune diseases
- EBV has been associated with lupus, rheumatoid arthritis, and other immune‑related conditions.
Cancers
- EBV is the first virus ever proven to cause cancer in humans. It is responsible for several lymphomas and epithelial cancers.
Severe complications in transplant patients
- People who receive organ or stem‑cell transplants are at high risk for EBV‑driven lymphomas because their immune systems are suppressed.
There is currently no way to prevent EBV infection
Unlike viruses such as HPV or hepatitis B, which have effective vaccines, EBV has no approved vaccine or antiviral therapy.
That means:
- Transplant patients remain vulnerable
- People with autoimmune disease risk factors have no preventive options
- EBV‑related cancers continue to occur worldwide
- The virus continues spreading silently through the population
Antibody therapy could change that
If these human antibodies can be developed into a safe therapy, they could:
- Protect transplant patients from EBV‑driven lymphoma
- Reduce EBV transmission in high‑risk settings
- Potentially lower the risk of EBV‑linked autoimmune diseases
- Provide a bridge until an EBV vaccine is available
This is similar to how monoclonal antibodies have been used to prevent RSV in infants or treat COVID‑19 in high‑risk patients.
How These Antibodies Could Be Used in the Future
1. Preventing EBV in transplant patients
This is the most immediate application. Transplant recipients often receive immune‑suppressing drugs, which makes them vulnerable to EBV‑driven cancers. A safe antibody therapy could dramatically reduce this risk.
2. Protecting EBV‑negative individuals
A small percentage of adults remain EBV‑negative. For them, primary infection can be severe. Antibody therapy could offer temporary protection during high‑risk periods (e.g., college dorms, military training).
3. Supporting EBV vaccine development
The study also identified new “vulnerable spots” on EBV proteins that could help guide vaccine design.
4. Treating EBV‑related diseases
While this study focused on prevention, future versions of these antibodies might help treat EBV‑driven cancers or chronic EBV‑related conditions.
Why This Study Stands Out
Several features make this research especially promising:
- The antibodies are fully human, reducing the risk of immune reactions
- They target two different EBV entry proteins, increasing the chance of blocking infection
- They were tested in a realistic humanized mouse model
- They showed strong protection, not just lab‑based activity
- They reveal new structural details that can guide future therapies
For a virus with no current treatment options, this represents a major step forward.
What Comes Next
Before these antibodies can be used in people, researchers will need to:
- Test them in more animal models
- Evaluate safety and dosing
- Explore combinations of gp350 and gp42 antibodies
- Begin early‑phase human trials
But the foundation is now in place.
For the first time, scientists have a set of fully human antibodies that can reliably block EBV infection in a living system.
Better Treatment, Lower Cost – No Catch.
Find safer, more effective medications with fewer side effects – often for less money. It’s fast, free, and personalized. Learn More →
Sources (4)
- Epstein‑Barr virus and cancer statistics – International Agency for Research on Cancer (IARC): https://www.iarc.who.int/featured-news/ebv-and-cancer
- EBV infection and multiple sclerosis risk – Science, 2022: https://www.science.org/doi/10.1126/science.abj8222
- EBV and autoimmune diseases – Nature Reviews Immunology: https://www.nature.com/articles/s41584-024-01167-9
- EBV risk in transplant patients – American Society of Transplantation: https://www.amjtransplant.org/article/S1600-6135(22)26266-2/fulltext